Journals / Turkish Journal of Pediatrics / 2020 / Cilt: 62 - Sayı: 4

Children with chronic-refractory autoimmune cytopenias: a single center experience

Pages
525–532
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Taking the new targeted treatment options into consideration; early diagnosis is likely to become more important in the near-future in order to begin the treatment for the underlying disease as early as possible.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and objectives.
📊
Key Findings & Data:Between February 1997 and September 2015, chronic/refractory autoimmune cytopenias patient data were evaluated retrospectively.
💡
Conclusion & Impact:Taking the new targeted treatment options into consideration; early diagnosis is likely to become more important in the near-future in order to begin the treatment for the underlying disease as early as possible.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Özet

Background and objectives. Autoimmune cytopenias are a group of heterogeneous disorders characterized by immune-mediated destruction of one or more hematopoietic lineage cells. The differential diagnosis of children with autoimmune cytopenias requires much time and laboratory investigations. The aim of the present study was to evaluate the clinical course and significance of autoimmune cytopenias due to immunodeficiency or autoimmune diseases in children at a single children’s hospital. Method. Between February 1997 and September 2015, chronic/refractory autoimmune cytopenias patient data were evaluated retrospectively. Twenty-three patients were assessed in this study. Results. The median duration of following was 2.6 years (4 months-18.5 years). The median age of diagnosis was 3.1 years (6 months-16 years). A total of 13 patients (56.5%) had single-lineage and 10 (46.5%) had multilineage cytopenias. The most frequent single-lineage cytopenia was thrombocytopenia, followed by anemia. In 22 of the patients, cytopenias was detected before the primary diseases. All of the patients were treated with corticosteroids or intravenous immune globulin as first-line treatment. Ten patients (43.5%) needed second or further-line immunosuppressive therapies that patients diagnosed as systemic lupus erythematosus, hypogammaglobulinemia, or common variable immunodeficiency. A total of 8 patients (34.7%) recovered from autoimmune cytopenias after the treatment of primer disease. Cytopenias were continued in 14 patients. Conclusion. Cytopenia may be the first finding of an immunodeficiency or autoimmune disease and primary disease may be diagnosed in the clinical course. Taking the new targeted treatment options into consideration; early diagnosis is likely to become more important in the near-future in order to begin the treatment for the underlying disease as early as possible.

🔖

Cite This Article

KARAPINAR, T. H., DURGUN, E., OYMAK, Y., GÜLEZ, N., AY, Y., GENEL, F., GÖZMEN, S., KÖKER, S. A., SERDAROĞLU, E., TORET, E., VERGİN, C. (2020). Children with chronic-refractory autoimmune cytopenias: a single center experience. Turkish Journal of Pediatrics, Cilt: 62 - Sayı: 4, 525–532. https://ajindex.com/articles/411964

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Miano M, Scalzone M, Perri K, et al. Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience. Br J Haematol 2015; 171: 247-253
  2. Price V. Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood. Pediatr Blood Cancer 2013; 60(Suppl 1): S12-S14
  3. Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood 2014; 124: 2337-2344
  4. Teachey DT, Lambert MP. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am 2013; 60: 1489- 1511
  5. Al Ghaithi I, Wright NA, Breakey VR, et al. Combined autoimmune cytopenias presenting in childhood. Pediatr Blood Cancer 2016; 63: 292-298
  6. Aladjidi N, Leverger G, Leblanc T, et al; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE). New insights into childhood autoimmune hemolytic anemia: a French National Observational Study of 265 children. Haematologica 2011; 96: 655-663
  7. Bride KL, Vincent T, Smith-Whitley K, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 2016; 127: 17-28
  8. Ghosh S, Seidel MG. Editorial: Current challenges in immune and other acquired cytopenias of childhood. Front Pediatr 2016; 4: 3
  9. Rao VK. Approaches to managing autoimmune cytopenias in novel immunological disorders with genetic underpinnings like autoimmune lymphoproliferative syndrome. Front Pediatr 2015; 3: 65
  10. Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005; 25: 57-62
  11. Aladjidi N, Fernandes H, Leblanc T, et al. Evans syndrome in children: long-term outcome in a Prospective French National Observational Cohort. Front Pediatr 2015; 3: 79
  12. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207
  13. Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson Textbook of Pediatrics. (18th ed). Philadelphia: Saunders Elsevier, 2007
  14. Dale DC, Bolyard AA, Schwinzer BG, et al. The severe chronic neutropenia International Registry: 10-year follow-up report. Support Cancer Ther